Literature DB >> 15935125

Second-generation antipsychotics and the metabolic syndrome.

Prakash S Masand1, Rajnish Mago.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15935125     DOI： 10.1007/s11920-005-0044-1

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN： 1523-3812            Impact factor:   5.285


× No keyword cloud information.
  6 in total

Review 1.  Consensus development conference on antipsychotic drugs and obesity and diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2004-02       Impact factor: 19.112

2.  Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care.

Authors:  Henry A Nasrallah; John W Newcomer
Journal:  J Clin Psychopharmacol       Date:  2004-10       Impact factor: 3.153

Review 3.  Understanding the new and evolving profile of adverse drug effects in schizophrenia.

Authors:  Donna A Wirshing; Joseph M Pierre; Stephen M Erhart; Jennifer A Boyd
Journal:  Psychiatr Clin North Am       Date:  2003-03

4.  The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists.

Authors:  John W Newcomer; Henry A Nasrallah; Antony D Loebel
Journal:  J Clin Psychopharmacol       Date:  2004-10       Impact factor: 3.153

Review 5.  Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

Authors:  Christoph U Correll; Stefan Leucht; John M Kane
Journal:  Am J Psychiatry       Date:  2004-03       Impact factor: 18.112

6.  Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia.

Authors:  Martina C M Ryan; Patrick Collins; Jogin H Thakore
Journal:  Am J Psychiatry       Date:  2003-02       Impact factor: 18.112
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.